[Suppression of graft versus host reaction by depositing a magnet-controlled adriamycin dosage form in bone marrow allotransplantation in animal experiments].
The main causes of failures during allogenous bone marrow transplantation is the development of graft versus host reactions. The methods of its prevention and treatment are the use of large doses of human toxic cytostatics and immunosuppressants aimed against donor immunocompetent cells. A way of preventing the adverse effects of cytostatics are targeted transport of long-acting cytostatic dosage forms to an organ or target cell through carriers, such as liposomes, microcapsules, microspheres and their conjugates with monoclonal antibodies. For this purpose, the study used gelatin and gum arabic microspheres containing the immunosuppressive cytostatic adriamycin. To enhance the efficiency of cytostatic depositing at the site of transplantation, the procedure of intraosseous transplantation of allogenous bone marrow transplantation with long-acting adriamycin depositing was developed. With this approach, the authors could not only deposit the agent, but could substantially increase the proportion of donor cells kept at the site of grafting as compared to the intravenous and intraosseous infusion of donor cells. The main advantage of the new technique of allogenous bone marrow transplantation in combination with a long-acting cytostatic dosage form is that acute and chronic graft versus host reactions can be inhibited long by using adriamycin in subtherapeutic dosages.
Pan'ko
S V
SV
Antipov
Iu G
IuG
Semenido
Iu N
IuN
Sosnovskaia
O Iu
OIu
Golovanova
T A
TA
Sanin
A V
AV
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers; D006087:Graft vs Host Reaction / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008863:Microspheres
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D007166:Immunosuppressive Agents; D004317:Doxorubicin